AIM ImmunoTech Inc. (AIM) DCF Valuation

AIM ImmunoTech Inc. (AIM) DCF Valuation
  • ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
  • ✓ Design Profissional: Modelos Confiáveis ​​E Padrão Da Indústria
  • ✓ Pré-Construídos Para Uso Rápido E Eficiente
  • ✓ Não É Necessária Experiência; Fácil De Seguir

AIM ImmunoTech Inc. (AIM) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Designed for accuracy, our AIM DCF Calculator enables you to assess AIM ImmunoTech Inc. (AIM) valuation using real-world financial data, offering complete flexibility to modify all essential parameters for improved projections.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .1 .2 .1 .1 .2 .2 .3 .3 .3 .4
Revenue Growth, % 0 16.43 -17.18 4.44 43.26 11.74 11.74 11.74 11.74 11.74
EBITDA -8.1 -13.0 -18.3 -19.9 -31.7 -.2 -.3 -.3 -.3 -.4
EBITDA, % -5820 -7988.96 -13522.22 -14091.49 -15682.18 -100 -100 -100 -100 -100
Depreciation .8 .7 .8 -.4 .2 .1 .2 .2 .2 .2
Depreciation, % 592.14 433.13 596.3 -300.71 117.82 60 60 60 60 60
EBIT -9.0 -13.7 -19.1 -19.4 -31.9 -.2 -.3 -.3 -.3 -.4
EBIT, % -6412.14 -8422.09 -14118.52 -13790.78 -15800 -100 -100 -100 -100 -100
Total Cash 8.8 39.0 48.3 34.2 13.1 .2 .3 .3 .3 .4
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .8 1.1 1.6 1.7 1.2
Account Receivables, % 585.71 689.57 1215.56 1188.65 586.14
Inventories .0 .0 .0 .0 -.3 .0 -.1 -.1 -.1 -.1
Inventories, % 0.000714285714 0 0 0 -149.5 -20 -20 -20 -20 -20
Accounts Payable .5 .4 .2 .4 6.4 .2 .3 .3 .3 .4
Accounts Payable, % 337.14 234.97 146.67 267.38 3189.6 100 100 100 100 100
Capital Expenditure -.4 -.6 -.6 -.3 -.6 -.2 -.3 -.3 -.3 -.4
Capital Expenditure, % -260.71 -365.03 -468.89 -192.2 -289.6 -100 -100 -100 -100 -100
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -10.2 -15.5 -21.4 -21.1 -31.9 -.2 -.3 -.3 -.3 -.4
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -10.1 -15.8 -22.0 -21.6 -25.4 -5.8 -.3 -.4 -.4 -.5
WACC, % 5.33 5.33 5.33 5.33 5.33 5.33 5.33 5.33 5.33 5.33
PV UFCF
SUM PV UFCF -6.9
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value -15
Present Terminal Value -11
Enterprise Value -18
Net Debt -5
Equity Value -14
Diluted Shares Outstanding, MM 49
Equity Value Per Share -0.28

What You Will Get

  • Pre-Filled Financial Model: AIM ImmunoTech Inc.'s (AIM) actual data provides an accurate DCF valuation.
  • Full Forecast Control: Modify revenue growth, profit margins, WACC, and other essential drivers.
  • Instant Calculations: Automatic updates allow you to view results in real-time as you make adjustments.
  • Investor-Ready Template: A polished Excel file crafted for high-quality valuation presentations.
  • Customizable and Reusable: Designed for adaptability, enabling repeated use for comprehensive forecasts.

Key Features

  • Customizable Research Parameters: Adjust key metrics such as clinical trial phases, market potential, and regulatory timelines.
  • Instant Valuation Calculations: Automatically computes intrinsic value, NPV, and other financial metrics with ease.
  • High-Precision Analysis: Leverages AIM ImmunoTech's actual financial data for credible valuation insights.
  • Effortless Scenario Testing: Explore various hypotheses and evaluate their impacts effortlessly.
  • Efficiency Booster: Streamline the valuation process without the hassle of creating complex models from the ground up.

How It Works

  1. Step 1: Download the Excel file.
  2. Step 2: Review pre-entered AIM ImmunoTech Inc. (AIM) data (historical and projected).
  3. Step 3: Adjust key assumptions (yellow cells) based on your analysis.
  4. Step 4: View automatic recalculations for AIM ImmunoTech Inc.'s intrinsic value.
  5. Step 5: Use the outputs for investment decisions or reporting.

Why Choose AIM ImmunoTech Inc. (AIM)?

  • Innovative Solutions: Pioneering research and development in immunotherapy.
  • Proven Results: Backed by scientific studies demonstrating efficacy and safety.
  • Strong Pipeline: A diverse range of promising therapies in various stages of development.
  • Expert Team: Led by seasoned professionals with extensive industry experience.
  • Commitment to Patients: Focused on improving patient outcomes and quality of life.

Who Should Use This Product?

  • Investors: Assess AIM ImmunoTech Inc.'s (AIM) potential value before making investment decisions.
  • CFOs: Utilize a professional-grade DCF model for accurate financial reporting and analysis related to AIM.
  • Consultants: Efficiently modify the template for valuation reports tailored to AIM's clients.
  • Entrepreneurs: Discover financial modeling techniques employed by leading biotech companies like AIM.
  • Educators: Incorporate it as a teaching resource to illustrate valuation methodologies in the biotech sector.

What the Template Contains

  • Historical Data: Includes AIM ImmunoTech Inc.'s (AIM) past financials and baseline forecasts.
  • DCF and Levered DCF Models: Detailed templates to calculate AIM ImmunoTech Inc.'s (AIM) intrinsic value.
  • WACC Sheet: Pre-built calculations for Weighted Average Cost of Capital.
  • Editable Inputs: Modify key drivers like growth rates, EBITDA %, and CAPEX assumptions.
  • Quarterly and Annual Statements: A complete breakdown of AIM ImmunoTech Inc.'s (AIM) financials.
  • Interactive Dashboard: Visualize valuation results and projections dynamically.

No products were found matching.